BLOCK LISTING SIX MONTHLY RETURN
May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Name of applicant: | Shire plc | |||
Name of scheme: | Shire Sharesave Scheme | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 184,611 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 17,079 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 167,532 | |||
Name of applicant: | Shire plc | |||
Name of scheme: | Shire Portfolio Share Plan | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 769,615 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 405,083 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 364,532 | |||
Name of applicant: | Shire plc | |||
Name of scheme: | Shire Employee Stock Purchase Plan | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 244,057 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 6,359 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 237,698 | |||
Name of applicant: | Shire plc | |||
Name of scheme: | Shire Long Term Incentive Plan 2015 | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 2,836,412 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 145,740 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,690,672 | |||
Name of applicant: | Shire plc | |||
Name of scheme: | Shire Global Employee Stock Purchase Plan | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 1,604,243 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 3,400 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,600,843 | |||
Name of applicant: | Shire plc | |||
Name of scheme: | Baxalta Exchange Awards | |||
Period of return: | From: | November 23, 2016 | To: | May 22, 2017 |
Balance of unallotted securities under scheme(s) from previous return: | 20,488,204 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 2,492,337 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 17,995,867 | |||
Name of contact: | Sarah Rixon, Company Secretarial Assistant |
Telephone number of contact: | 01256 894000 |
For further information please contact:
Investor Relations | ||
Ian Karp | ikarp@shire.com | +1 781 482 9018 |
Robert Coates | rcoates@shire.com | +44 1256 894874 |
Media | ||
Lisa Adler | lisa.adler@shire.com | +1-617 588 8607 |
Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
Shire plc published this content on 23 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 May 2017 11:30:24 UTC.
Original documenthttp://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=876111
Public permalinkhttp://www.publicnow.com/view/71BE19F767AF09F565C057AFC2D16206642F015C